Table 3 TGCT-related therapies prior to baseline, N (%)

Any surgery prior to baseline

57 (60.0)

71 (100)

128 (77.1)

Type of surgery prior to BL (if any)^a

 Arthroscopic synovectomy

30 (31.6)

33 (46.5)

63 (49.2)

 One-stage synovectomy

22 (23.2)

42 (59.2)

64 (50.0)

 Two-stage synovectomy

6 (6.3)

7 (9.6)

13 (10.2)

 (Tumor) prosthesis

1 (1.1)

4 (5.6)

5 (3.9)

Any systemic treatment prior BL

24 (25.3)

28 (39.4)

52 (31.3)

Type of last systemic treatment prior BL (if any)

 Tyrosine kinase inhibitors

22 (91.7)

25 (89.3)

47 (90.4)

 Monoclonal antibodies

1 (4.2)

3 (10.7)

4 (7.7)

 Other

1 (4.2)

–

1 (1.9)

 Duration [days] until BL,

 Median (Q1, Q3)

307.00

(120.00–421.00)

186.00

(88.00–345.00)

236.00

(118.00–366.00)

 Ongoing

11 (45.8)

7 (25.0)

18 (34.6)

 Possible side effects

11 (45.8)

19 (67.8)

30 (58.8)

Any radiation therapy

5 (5.3)

10 (14.1)

15 (9.0)

Type of radiation therapy prior to BL (if any)

 Radiotherapy

2 (40.0)

4 (40.0)

6 (40.0)

 ⁹⁰Yttrium

3 (60.0)

6 (60.0)

9 (60.0)

No prior therapy

27 (28.4)

–

27 (16.3)

Prior and concomitant therapies for TGCT-related symptoms

50 (52.6)

38 (53.5)

88 (53.0)